NASDAQ:EYES - Second Sight Medical Products Stock Price, Forecast & News

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Second Sight Medical Products Inc (NASDAQ:EYES) posted its quarterly earnings data on Thursday, November, 14th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.06). The medical device company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.94 million. Second Sight Medical Products had a negative net margin of 743.86% and a negative return on equity of 201.34%. View Second Sight Medical Products' Earnings History.

Second Sight Medical Products is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Second Sight Medical Products.

1 brokers have issued 1-year price objectives for Second Sight Medical Products' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Second Sight Medical Products' stock price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 63.0%. View Analyst Price Targets for Second Sight Medical Products.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.

Headlines about EYES stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Second Sight Medical Products.

Second Sight Medical Products saw a drop in short interest in January. As of January 31st, there was short interest totalling 516,200 shares, a drop of 87.3% from the January 15th total of 4,070,000 shares. Based on an average daily volume of 37,800 shares, the days-to-cover ratio is presently 13.7 days. Currently, 91.8% of the shares of the company are sold short. View Second Sight Medical Products' Current Options Chain.

Some companies that are related to Second Sight Medical Products include BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM), IRIDEX (IRIX), Fc Global Realty (FCRE), electroCore (ECOR), Helius Medical Technologies (HSDT), Precision Optics (PEYE), ENDRA Life Sciences (NDRA) and Digirad (DRAD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Opko Health (OPK), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), TransEnterix (TRXC), Plug Power (PLUG) and Canopy Growth (CGC).

(EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

Second Sight Medical Products' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sigma Planning Corp (2.43%) and B. Riley Wealth Management Inc. (0.23%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland. View Institutional Ownership Trends for Second Sight Medical Products.

EYES stock was sold by a variety of institutional investors in the last quarter, including Sigma Planning Corp and B. Riley Wealth Management Inc.. Company insiders that have sold Second Sight Medical Products company stock in the last year include Edward David Randolph and Jonathan Will Mcguire. View Insider Buying and Selling for Second Sight Medical Products.

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYES stock can currently be purchased for approximately $5.41.

Second Sight Medical Products has a market capitalization of $84.23 million and generates $6.90 million in revenue each year. The medical device company earns $-35,090,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.View Additional Information About Second Sight Medical Products.

The official website for Second Sight Medical Products is http://www.secondsight.com/.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]